EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Personalized outcomes in neuropathic pain: a clinical relevance and assay sensitivity analysis from a randomized controlled trial

Karim Saab iD, Umang Gada, Eva Culakova, Brian Burnette, Carla Jorgensen, Dhaval Shah, Gary Morrow, Karen Mustian, Michael B Sohn, Robert R Edwards, Roy Freeman, Dale J Langford und 2 weitere

Pain Medicine · 2025

DOI: 10.1093/pm/pnae095 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pain Medicine, 2025. Verfasst von Karim Saab und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, United States. Hauptthemen laut MEDLINE: Neuralgia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To explore the clinical relevance and assay sensitivity of using personalized outcomes using data from a randomized clinical trial (RCT) in people with chemotherapy-induced peripheral neuropathy (CIPN).

Design

This study is a secondary analysis that leveraged data from a RCT of transcutaneous electrical stimulation for CIPN to test whether personalized outcomes could minimize potential floor effects and increase the assay sensitivity of pain clinical trials (ie, ability to detect a true treatment effect).

Setting

Participants were recruited for a RCT from community oncology clinics in the United States.

Participants

Adults with CIPN (N = 72) who reported on average ≥4 intensity (measured via a 7-day baseline diary) for at least 1 of the following pain qualities: hot/burning pain, sharp/shooting pain, and/or cramping.

Methods

Personalized outcomes were defined based on participants’ unique presentation of pain qualities at baseline, measured via 0-10 numeric rating scales (NRS), or ranking of the distress caused by the pain qualities. Analysis of covariance models estimated the treatment effect as measured by personalized and non-personalized outcomes.

Results

The adjusted mean difference between groups was higher using personalized outcomes (ie, 1.21-1.25 NRS points) compared to a non-personalized outcome (ie, 0.97 NRS points), although the standardized effect sizes were similar between outcomes (0.49-0.54).

Conclusions

These results suggest that personalized pain quality outcomes could minimize floor effects, while providing similar assay sensitivity to non-personalized pain quality outcomes. Personalized outcomes better reflect an individual’s unique experience, inherently providing more clinically relevant estimates of treatment effects. Personalized outcomes may be advantageous, particularly for clinical trials in populations with high inter-individual variability in pain qualities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuralgiaHumansFemaleMaleMiddle AgedAgedPain MeasurementAdultPrecision MedicineTranscutaneous Electric Nerve StimulationTreatment OutcomeAntineoplastic AgentsClinical Relevance

Stichwörter der Autor:innen

assay sensitivitychemotherapy-induced peripheral neuropathyinter-individual variabilityneuropathic painpersonalized outcomes

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, United States.
  • Department of Surgery, Supportive Care in Cancer, University of Rochester Medical Center, Rochester, NY 14642, United States.
  • Cancer Research of Wisconsin and Northern Michigan NCORP, Green Bay, WI 54301, United States.
  • NCORP of the Carolinas-Prisma Health NCORP/Greenville, Greenville, SC 29605, United States.
  • Helen F. Graham Cancer Center and Research Institute, Christiana Care, Newark, DE 19713, United States.
  • Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY 14624, United States.

ORCID-Profile: Karim Saab, Jennifer S Gewandter

Förderung

  • NINDS NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • Neurometrix
  • National Institutes of Health

Zitieren

APA

Saab, K., Gada, U., Culakova, E., Burnette, B., Jorgensen, C., Shah, D., Morrow, G., Mustian, K., Sohn, M. B., Edwards, R. R., Freeman, R., Langford, D. J., McDermott, M. P., & Gewandter, J. S. (2025). Personalized outcomes in neuropathic pain: a clinical relevance and assay sensitivity analysis from a randomized controlled trial. Pain Medicine. https://doi.org/10.1093/pm/pnae095

Vancouver

Saab K, Gada U, Culakova E, Burnette B, Jorgensen C, Shah D, et al. Personalized outcomes in neuropathic pain: a clinical relevance and assay sensitivity analysis from a randomized controlled trial. Pain Medicine. 2025. doi:10.1093/pm/pnae095

BibTeX
@article{Saab2025,
  author = {Saab, Karim and Gada, Umang and Culakova, Eva and Burnette, Brian and Jorgensen, Carla and Shah, Dhaval and Morrow, Gary and Mustian, Karen and Sohn, Michael B and Edwards, Robert R and Freeman, Roy and Langford, Dale J and McDermott, Michael P and Gewandter, Jennifer S},
  title = {Personalized outcomes in neuropathic pain: a clinical relevance and assay sensitivity analysis from a randomized controlled trial},
  journal = {Pain Medicine},
  year = {2025},
  doi = {10.1093/pm/pnae095}
}
Kostenlos starten →